Non-Hodgkin Lymphoma | Specialty

Potential of R2 Regimen in Treating Follicular Lymphoma

January 19th 2019

Strategies for Therapeutic Sequencing Agents

January 19th 2019

Long-Term Efficacy and Safety of Copanlisib

January 19th 2019

Use of PI3K Inhibitors in Relapsed Follicular Lymphoma

January 19th 2019

Third-Line Treatments and Transplantation

January 19th 2019

Treating Relapsed or Refractory Follicular Lymphoma

January 19th 2019

Maintenance Therapy and MRD Testing in Follicular Lymphoma

January 19th 2019

Treatment Options for High-Risk Follicular Lymphoma Cases

January 19th 2019

Up-Front Therapy in Follicular Lymphoma

January 19th 2019

Risk Assessment in Follicular Lymphoma

January 19th 2019

Diagnosis and Prognosis of Follicular Lymphoma

January 19th 2019

Targeting BCL-2 in Hematologic Malignancies

January 11th 2019

Over the past 2 decades, considerable efforts have focused on the development of therapies that can restore apoptosis in malignant cells.

BCL-2: Mechanisms and Prevalence

January 10th 2019

The understanding of the BCL2 oncogene and the BCL-2 protein family have motivated the current advancements in cancer therapeutics that target different members of apoptotic regulatory networks.

Dr. Horwitz Discusses the Results of the ECHELON-2 Study

December 13th 2018

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the ECHELON-2 study in patients with CD30+ peripheral T-cell lymphomas (PTCL).

Selinexor Promotes Deep, Durable Responses in Relapsed/Refractory DLBCL

December 11th 2018

Selinexor monotherapy induced deep and durable responses in the phase IIb SADAL study of patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplantation.

Robust Future Ahead for Stem Cell Transplants

December 6th 2018

Although many new drugs have been introduced for treating patients with hematologic malignancies, stem cell transplantation remains a vital part of the therapeutic paradigm, particularly for multiple myeloma and non-Hodgkin lymphoma.

Update Details Brentuximab Vedotin Survival Benefit in CD30+ PTCL

December 5th 2018

The addition of brentuximab vedotin to chemotherapy led to a clinically meaningful improvement in progression-free and overall survival in patients with CD30-expressing peripheral T-cell lymphoma.

Dr. Poeschel on 6 Versus 4 Cycles of R-CHOP in Frontline DLBCL

December 4th 2018

Viola Poeschel, MD, department of hematology, oncology and rheumatology, Saarland University Medical School, Germany, discusses outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with 4 cycles of R-CHOP during the 2018 ASH Annual Meeting.

Dr. Andreadis on the Treatment of Relapsed DLBCL

December 4th 2018

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the treatment of patients with relapsed diffuse large B-cell lymphoma.

Lenalidomide/Rituximab Improves PFS in Indolent Non-Hodgkin Lymphoma

December 3rd 2018

The R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) reduced the risk of disease progression or death by 54% versus rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma.